The Study of Gut Associated Lymphocytes in HIV and HCV/HIV Co-infected Patients

This study has been completed.

Sponsor:

Collaborator:

Merck Sharp & Dohme Corp.

Information provided by (Responsible Party):

Mohamed Tarek Shata, University of Cincinnati

ClinicalTrials.gov Identifier:

NCT01335230

First received: April 12, 2011

Last updated: August 27, 2015

Last verified: August 2015

History of Changes

Purpose

The purpose of this research study is to explore what role immune cells within the gut (the sigmoid colon) have locally and on the immune system of patients infected with HCV, HIV or HCV/ HIV co-infection.

Condition
HIV Hepatitis C, Chronic HCV Coinfection


Study Type:	Observational
Study Design:	Observational Model: Case Control Time Perspective: Cross-Sectional
Official Title:	Exploring the Role of Gut-associated TH17 in Microbial Translocation in HIV and HCV/HIV Co-infected Patients

Resource links provided by NLM:

MedlinePlus related topics: HIV/AIDS Hepatitis Hepatitis A Hepatitis C

U.S. FDA Resources

Further study details as provided by University of Cincinnati:

Primary Outcome Measures:

Exploring the Role of Gut-associated Th17 in Microbial Translocation in HIV and HCV/HIV Coinfected Patients. [ Time Frame: One year ] [ Designated as safety issue: Yes ]
We measure gene transcription of the colon tissues (relative expression fold changes of gene transcription compared to control). No preselected criteria were used to assess the participants. Data were analyzed and compared among each group. Relative expression levels of LEAP-2 (Liver expressed anti-microbial peptide-2) in the four groups were shown in the table below. Detailed of other genes had been published in Shata MT, et al, J. Clin Pathology 2013, Nov 66(11):967-75. PMID 23940131, and Abdel-Hameed et al, J. Acquir Immune Defic Syndr. 2013 Jul 10 PMID: 23846566

Biospecimen Retention: Samples With DNA

Colon tissues


Enrollment:	40
Study Start Date:	April 2011
Study Completion Date:	January 2013
Primary Completion Date:	January 2013 (Final data collection date for primary outcome measure)

Groups/Cohorts
10 HIV mono-infected subjects 10 subjects infected with HIV only
10 HCV mono-infected subjects 10 subjects infected with HCV only
10 HIV/HCV co-infected subjects 10 subjects infected with both HIV and HCV
10 control subjects 10 subjects without HIV, HCV, or both

Detailed Description:

Objective 1: Characterization of the Gut Associated Lymphocytes (GALT) in HIV, HCV and coinfected patients regarding the role of Th17 and cytokine profiles.

Hypothesis 1a: HIV and HCV/HIV coinfection is associated with changes in Th17 numbers and functions in GALT.

Hypothesis 1b: HIV and HCV/HIV coinfection is associated with changes in cytokine profiles in intestinal mucosa.

Objective 2: Identify the relationship between changes in Gut Associated Lymphocytes (GALT) in HIV, HCV and coinfected patients and markers of microbial translocation.

Hypothesis 2a: Changes in GALT are associated with increase in microbial translocation in HIV, HCV and coinfected patients.

Eligibility


Ages Eligible for Study:	18 Years to 70 Years (Adult, Senior)
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes
Sampling Method:	Non-Probability Sample

Study Population

The investigators plan to enroll 40 human subjects including 10 HIV mono-infected, 10 HCV mono-infected, 10 HIV/HCV co-infected patients, and 10 control subjects from the outpatient clinic at the University of Cincinnati College of Medicine.

Criteria

Inclusion Criteria:

are at least age 18, but not older than 70 years old
have HIV, HCV or both
do not have HIV, HCV or both, and are having a screening colonoscopy or flexible sigmoidoscopy for abdominal pain or colon cancer screening (control subject)

Exclusion Criteria:

have a history of inflammatory bowel diseases (IBD) or suspected IBD
have a history of autoimmune diseases including rheumatoid arthritis
are taking systemic immunomodulators
are pregnant

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01335230

Locations


United States, Ohio
University of Cincinnati
Cincinnati, Ohio, United States, 45267

Sponsors and Collaborators

University of Cincinnati

Merck Sharp & Dohme Corp.

Investigators


Principal Investigator:	M. Tarek Shata, MD, PhD	University of Cincinnati

More Information

Publications:

Shata MT, Abdel-Hameed EA, Hetta HF, Sherman KE. Immune activation in HIV/HCV-infected patients is associated with low-level expression of liver expressed antimicrobial peptide-2 (LEAP-2). J Clin Pathol. 2013 Nov;66(11):967-75. doi: 10.1136/jclinpath-2013-201581. Epub 2013 Aug 12.

Abdel-Hameed EA, Ji H, Sherman KE, Shata MT. Epigenetic modification of FOXP3 in patients with chronic HIV infection. J Acquir Immune Defic Syndr. 2014 Jan 1;65(1):19-26. doi: 10.1097/QAI.0b013e3182a1bca4.


Responsible Party:	Mohamed Tarek Shata, Principal Investigator, University of Cincinnati
ClinicalTrials.gov Identifier:	NCT01335230 History of Changes
Other Study ID Numbers:	UC 10110905
Study First Received:	April 12, 2011
Results First Received:	June 24, 2013
Last Updated:	August 27, 2015
Health Authority:	United States: Institutional Review Board

Keywords provided by University of Cincinnati:


HIV HCV Hepatitis C HIV and Hepatitis C coinfection HIV/HCV

Additional relevant MeSH terms:


Hepatitis Hepatitis C Hepatitis C, Chronic Coinfection Liver Diseases Digestive System Diseases Hepatitis, Viral, Human	Virus Diseases Flaviviridae Infections RNA Virus Infections Hepatitis, Chronic Infection Parasitic Diseases

ClinicalTrials.gov processed this record on September 30, 2016

To Top